B-Cell Lymphoma (Lymphoma, B Cell)

08/01/2013 - "The introduction of rituximab, an anti-CD20 monoclonal antibody, has dramatically improved the treatment outcomes of patients with B cell lymphoma. "
07/15/2012 - "The use of IFRT in patients with primary mediastinal B-cell lymphoma who achieved complete response remain as the best treatment available, even in patients that received rituximab during induction."
01/01/2010 - "Because of the excellent results achieved with PA therapy, the potential role of rituximab (an anti-CD20 monoclonal antibody that is highly effective against most B-cell lymphomas) in HCL has yet to be elucidated. "
02/24/2011 - "Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. "
03/01/2010 - "Despite its excellent safety and efficacy profile, only a small portion of B-cell lymphoma patients treated with rituximab as a single agent have sustained complete remissions. "

03/01/1999 - "Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model."
11/01/2013 - "Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma."
02/01/2012 - "When loaded with a toxic cargo such as doxorubicin, they are efficacious in prolonging life in a Daudi B cell lymphoma model. "
05/01/2011 - "The B-cell lymphoma MDR sublines were developed by exposing the parental Daudi cells to stepwise increasing concentrations of doxorubicin. "
08/01/1998 - "In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma."

07/01/2008 - "The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma."
08/15/2005 - "Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells."
01/01/1989 - "The CD4 cell dependency of SJL/J B-cell lymphomas as a target for cyclophosphamide therapy."
01/01/2013 - "A 31-year-old woman with primary mediastinal large B-cell lymphoma refractory to conventional chemotherapy was treated with high-dose chemotherapy containing cyclophosphamide (CY). "
08/01/2010 - "Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET."

01/01/2008 - "The effects of VAQuFrF on the B cell lymphoma cell line WSU-1 were comparable to those of vincristine in all parameters. "
01/01/2008 - "In this study, the effects of Viscum album (VA) QuFrF extract and vincristine were compared on B cell lymphoma cell line WSU-1 in an in vitro model. "
06/04/2012 - "Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma."
01/01/2008 - "Comparison of Viscum album QuFrF extract with vincristine in an in vitro model of human B cell lymphoma WSU-1."
02/01/2004 - "In a murine model of human B-cell lymphoma, we have made in vitro and in vivo comparisons of long-circulating sterically stabilized (Stealth) immunoliposome (SIL) formulations of two anticancer drugs, vincristine (VCR) and doxorubicin (DXR), with different mechanisms of action and drug release rates. "

01/01/2005 - "Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone."
02/01/1999 - "Four such hypercalcemic patients with stage IV B-cell lymphoma were treated, two each, with either 400 mg daily oral hydroxychloroquine or a single course of prednisone-containing antitumor chemotherapy (CHOP). "
04/01/2004 - "We conducted a controlled clinical trial to evaluate the efficacy and toxicity of interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy in patients with aggressive diffuse large B cell lymphomas in complete remission after aggressive chemotherapy. "
02/01/1989 - "We have documented seven B cell lymphomas over a six-month period in 132 (5.3%) kidney and heart allograft recipients immunosuppressed with cyclosporine, azathioprine, and prednisone (triple therapy). "
08/01/2004 - "We present a 46-year-old woman with dermatomyositis, who developed an EBV-associated B-cell lymphoma of the brain while on oral methotrexate, mycophenolate mofetil and low-dose prednisone. "

03/01/2003 - "These results suggest that anti-CD20 pretargeted RIT may be superior to conventional radiolabeled antibodies in terms of radioimmunoscintigraphy, toxicity, and therapeutic efficacy for treatment of B-cell lymphomas."
09/15/1998 - "Anti-idiotype (Id) antibodies (Abs) have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials. "
05/01/2011 - "The development of human antibodies specific for certain B cell markers is required to generate therapeutic antibody leads with improved therapeutic indices against B-cell lymphomas. "
12/01/2005 - "These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas."
10/21/1993 - "We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 and 1F5) and anti-CD37 (MB-1) antibodies labeled with iodine-131 in 43 patients with B-cell lymphoma in relapse. "

01/05/2000 - "Microenvironmental factors reduce the sensitivity of a B-cell lymphoma to etoposide in vitro by modulating the expression and functions of Bax and Bcl-x(L). "
02/01/2004 - "Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins."
07/18/2014 - "High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6."
09/01/2008 - "Here, we confirmed that stable expression of B-cell lymphoma-xL (Bcl-xL) in N18TG neuroglioma cells could suppress c-Jun N-terminal protein kinase (JNK) activation, nuclear fragmentation, and cell death caused by etoposide treatment. "
10/01/2005 - "Here we examine the role of p38 in regulation of apoptosis and cell cycle checkpoint in Daudi B-cell lymphoma cells treated with the topoisomerase II inhibitor etoposide. "

07/28/1995 - "Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone."
11/01/1997 - "We demonstrate in these preclinical studies that all severe combined immunodeficient mice injected with the human B-cell lymphoma cell line Ramos are cured when treated with a combination of anti-CD19, -CD22, and -CD38-saporin immunotoxins (ITs; termed 3BIT). "
08/15/1996 - "A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma."
07/28/1995 - "CD19 and CD38 are expressed on the surface of the vast majority of B-cell lymphoma and common acute lymphoblastic leukaemia cells, and our findings provide a sound rationale for a combination immunotoxin trial in these diseases directed against both these target molecules."
06/15/1995 - "Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study."

01/01/2014 - "Further accumulation of cases is needed to clarify which biologics are safe and effective for treatment of methotrexate-associated B-cell lymphoma."
09/01/2012 - "In this study, we investigated the effects of SA981, an active metabolite of Buc, and methotrexate (MTX) on CD40-mediated antibody production using mouse B-cell lymphoma, BCL1. "
03/01/2015 - "[Subacute encephalopathy after high-dose methotrexate as prophylaxis for central nervous system relapse in a patient with intravascular large B-cell lymphoma]."
04/01/2010 - "The latter stained as B cells (CD20), enabling a diagnosis of B-cell lymphoma, and the condition responded fully to high-dose methotrexate. "
01/01/2010 - "Thus, this patient was classified as having a rare form of an EBV-negative primary cutaneous T-cell-rich B-cell lymphoma in association with methotrexate treatment."

01/01/2007 - "In this article, we will review how recent advances in our understanding of the properties of antigen-specific T cells that facilitate their long-term persistence in vivo and reversion to the memory pool after in vitro culture, combined with approaches to molecularly engineer T cells with receptors that target molecules expressed by B-cell lymphoma, are providing opportunities to broaden the application of T-cell therapy and improve its efficacy for this disease."
10/01/1998 - "Early clinical trials in B-cell lymphomas demonstrated both the potential and limitations of unlabeled murine monoclonal antibody therapy, and taught us valuable lessons regarding the importance of the antibody structure, and nature of the targeted antigen. "
01/01/1991 - "Immunohistochemical studies showed that this represented a B-cell lymphoma, staining positively for leucocyte common antigen and five B-lineage markers L26, MB2, B1 (CD20), B4 (CD19) and To15 (CD22). "
07/01/2015 - "CD20, a membrane antigen broadly expressed in mature B cells and in B cell lymphomas, is subject to an alternative splicing named D393-CD20 leading to loss of membrane expression of the spliced isoform. "
02/01/2015 - "Thus, lymphomagenesis associated with pSS exemplifies the development of antigen-driven B-cell lymphoma. "

01/01/2007 - "The immuno-chemotherapy has dramatically improved the outcome of diffuse large B-cell lymphomas patients. "
12/01/2008 - "With the diagnosis of large B cell lymphoma, chemotherapy was prescribed for the first patient, and the patient has been in complete remission for more than 5 months. "
12/01/2008 - "With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%). "
01/01/2001 - "The girl was re-admitted and, after a complete re-staging, chemotherapy was intensified according to our schedule for high-grade B-cell lymphoma and CNS was irradiated up to a total dose of 25 Gy. She remained alive in continuous complete remission at 21 months after diagnosis. "
05/15/1997 - "That these factors appear to act together to enhance proliferative potential after DNA damage has important implications regarding the development of drug resistance in B-cell lymphomas and future strategies for improved chemotherapy."

08/01/2014 - "Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data. "
01/01/2003 - "For more than a decade, radioimmunotherapy has shown great promise for the treatment of B-cell lymphoma. "
10/01/1998 - "Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. "
11/10/2008 - "Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas."
01/01/2002 - "In this study we investigated the efficacy and toxicity of 131I-labelled-LL2 for radioimmunotherapy in patients with B-cell lymphomas that failed one or two cytostatic regimens. "

01/01/2002 - "Local radiotherapy was started and combined photon and electron beam irradiation induced complete remission of the B-cell lymphoma."
11/15/2008 - "MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma."
07/01/2014 - "In the present study, we describe the use of electrochemotherapy as alternative therapy for primary cutaneous marginal zone B-cell lymphomas in patients unsuitable for surgery or radiotherapy. "
01/01/2013 - "She was treated with surgery and radiotherapy and diagnosed with a mature B-cell lymphoma based on gene rearrangement studies. "
01/08/2015 - "Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313."

11/01/2015 - "Recent studies reported the therapeutic efficacy in mice bearing B-cell lymphoma xenografts following treatment with the anti-CD20-hIFNα fusion protein. "
10/04/2010 - "Using a Cy5-labeled aptamer TD05 (Cy5-TD05) as the probe, the in vivo efficacy of aptamer-based molecular imaging in Ramos (B-cell lymphoma) xenograft nude mice was tested. "
07/01/1998 - "The SU-DHL-4 B cell lymphoma xenotransplantation model was used as an in vivo system for testing the efficacy of cellular therapy. "
01/01/2015 - "In this proof-of-concept study in human cell culture and orthotopic xenografts, we conclude that a fluorescent switchable aptamer can provide rapid and specific labeling of B-cell lymphoma, and that developing aptamer-based labeling approaches could simplify tissue staining and drastically reduce time to histopathological diagnoses compared with IHC-based methods. "
01/01/1993 - "Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts."

09/01/2008 - "Several trials have established the efficacy of autologous stem cell transplantation for relapsed diffuse large B-cell lymphomas, but the benefit has been largely restricted to patients with chemosensitive disease and low-risk features at the time of relapse. "
04/01/2014 - "In this study, we identified 260 cases of non-Burkitt, diffuse aggressive B-cell lymphomas from SWOG S9704, a phase 3 randomized study of standard immunochemotherapy versus autologous stem cell transplantation. "
08/05/1995 - "Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas."
06/01/2014 - "Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation."
07/01/2008 - "Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation."